Molecular 'on-off' switch for Parkinson's disease discovered

(Medical Xpress) -- Scientists at the Medical Research Council (MRC) Protein Phosphorylation Unit at the University of Dundee have discovered a new molecular switch that acts to protect the brain from developing Parkinson's disease.

The findings have helped scientists understand how in a gene called PINK1 lead to Parkinson's in patients as young as 8 years old - which could eventually lead to new ways to diagnose and treat the condition.

The job of some proteins inside cells is to switch other important proteins on or off. Understanding how these proteins work and which proteins they target could be the key to why die in Parkinson's - and how we can save them.

But despite intensive research, the target of the PINK1 enzyme (which is made by the PINK1 gene) has eluded scientists for almost a decade.

Now the Dundee team has found that PINK1 switches on a protein called , whose main job is to keep cells healthy by removing damaged proteins. Mutations in the gene that makes Parkin can also cause inherited forms of Parkinson's in younger patients .

The team was led jointly by Dr Miratul Muqit and Professor Dario Alessi at the University of Dundee.

"Parkinson's is a devastating and currently we have no drugs in the clinic that can cure or slow the disease down," said Dr Muqit, a Wellcome Trust Clinician Scientist in the MRC Unit.

"Over the last decade, many genes have been linked to Parkinson's but a major roadblock has been determining the function of these genes in the brain and how the mutations lead to brain degeneration."

Dr Muqit said, "Our work suggests this pathway can't be switched on in Parkinson's patients with genetic mutations in or Parkin. More research will be needed to see whether this also happens in Parkinson's patients who do not carry these mutations."

Professor Alessi, Director of the MRC Phosphorylation Unit, added, "Now that we have identified this pathway, the key next step will be to identify the nature of these damaged proteins that are normally removed by Parkin. Although further studies are required, our findings also suggest that designer drugs that switch this pathway on could be used to treat Parkinson's."

The research was funded by the Medical Research Council, Wellcome Trust, Parkinson's UK, the J. Macdonald Menzies Charitable Trust and the Michael J. Fox Foundation.

The research is published in the latest edition of the journal Open Biology. The paper was co-authored with Dr Helen Walden from Cancer Research UK's London Research Institute.

Related Stories

New insight into Parkinson's disease

Apr 19, 2010

New research provides crucial insight into the pathogenic mechanisms of Parkinson's disease (PD), a prevalent neurodegenerative disorder. The study appears in the April 19 issue of the Journal of Cell Biology.

Vitamin K2: New hope for Parkinson's patients?

May 11, 2012

Neuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients. ...

Why do neurons die in Parkinson's disease?

Nov 10, 2011

Current thinking about Parkinson's disease is that it's a disorder of mitochondria, the energy-producing organelles inside cells, causing neurons in the brain's substantia nigra to die or become impaired. A study from Children's ...

Recommended for you

Gait and dementia link confirmed

Oct 22, 2014

Researchers at Newcastle University have found a definitive link between gait - the way someone walks - and early changes in cognitive function in people with Parkinson's disease.

Parkinson's disease may start in the gut

Oct 14, 2014

Parkinson's disease is strongly linked to the degeneration of the brain's movement center. In the last decade, the question of where the disease begins has led researchers to a different part of the human anatomy. In 2003, ...

User comments